Skip to search formSkip to main contentSkip to account menu

BRL-26921

Known as: BRL 26921, BRL26921 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

Anistreplase

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
1990
1990
Modern strategies for treatment of acute myocardial infarction: significance of haemostaseological and rheological findings.
In spite of equivalent clinical efficacy of various thrombolytic agents for the treatment of acute myocardial infarction there is… 
1987
1987
High-dose systemic streptokinase and acylated streptokinase-plasminogen complex (BRL 26921) in acute myocardial infarction: alterations of the fibrinolytic system and clearance of fibrinolytic…
We report the results of two consecutive studies using intravenous bolus injections of streptokinase (SK) or acylated plasminogen… 
1987
1987
Systemic Effects of Thrombolytic Drugs in Acute Myocardial Infarction: Comparison of Intravenous APSAC (BRL 26921) and Intracoronary Streptokinase
1986
1986
Die Bolusinjektion von anisoyliertem Plasminogen-Streptokinase-Aktivator-Komplex (BRL 26921) als alternatives Konzept der systemischen Lyse bei akutem Myokardinfarkt
SummaryThe thrombolytic properties of anisoylated plasminogen streptokinase activator complex (BRL 26921) and clinical results of… 
1986
1986
[Bolus injection of anisoylated plasminogen-streptokinase activator complex (BRL 26921) as an alternative concept of systemic lysis in acute myocardial infarct].
The thrombolytic properties of anisoylated plasminogen streptokinase activator complex (BRL 26921) and clinical results of the… 
1985
1985
The use of BRL26921 (APSAC) as fibrinolytic therapy in acute myocardial infarction.
1985
1985
Efficacy of BRL 26921, a new fibrinolytic agent for intravenous infusion, in acute myocardial infarction
The main goal of therapeutic thrombolysis in acute myocardial infarction is early reperfusion of acutely obstructed coronary… 
1985
1985
Induction of a sustained fibrinolytic response by BRL 26921 in vitro.
1985
1985
BRL 26921, A new thrombolytic agent for pulmonary embolism
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)